超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Endo Pharmaceuticals Endo Health Solutions   
Endo藥物公司成立于1997年,是一家專業(yè)制藥公司的研究，開發(fā)，銷售和品牌和非專利處方藥，用于治療和管理的疼痛，膀胱癌，前列腺癌和青春期的兒童，或中樞性性早熟（人民黨早發(fā)從事藥品營銷）。其產(chǎn)品包括LIDODERM（R）的一個(gè)專題片，以減輕疼痛的帶狀皰疹后遺神經(jīng)痛;波拷賽特（R）和Percodan（注冊(cè)商標(biāo)）為中度至重度疼痛片;弗羅瓦（R）用于治療急性粒偏頭痛的攻擊或無成人先兆; OPANA（R）的片用于中度至重度急性疼痛的阿片類藥物如使用適當(dāng)?shù)木葷?jì); OPANA（R）的急診室為救濟(jì)片中度至重度疼痛患者需要一個(gè)較長時(shí)期的持續(xù)，大約24小時(shí)阿片類藥物治療;扶他林（R）的凝膠，它是由諾華公司擁有，非類固醇消炎藥物對(duì)骨關(guān)節(jié)炎疼痛表示許可關(guān)節(jié)經(jīng)得起局部治療，如手和膝蓋的活動(dòng);為晚期前列腺癌的姑息治療VANTAS（注冊(cè)商標(biāo)）; SUPPRELIN（R）的洛杉磯為在青春期兒童的早期發(fā)病治療;及瓦爾斯塔爾（商標(biāo)）卡介苗為難治性原位癌的患者膀胱（獨(dú)聯(lián)體）治療膀胱切除術(shù)的人立即將與不可接受的醫(yī)療風(fēng)險(xiǎn)有關(guān)。該公司銷售其品牌產(chǎn)品在痛苦中醫(yī)藥管理，泌尿，內(nèi)分泌學(xué)，腫瘤學(xué)，神經(jīng)病學(xué)，外科和初級(jí)保健醫(yī)生。


Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM?, a topical patch to relieve the pain of postherpetic neuralgia; Percocet? and Percodan? tablets for the relief of moderate-to-moderately severe pain; FROVA? tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA? tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA? ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren? Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTAS? for the palliative treatment of advanced prostate cancer; SUPPRELIN? LA for the treatment of early onset puberty in children; and VALSTAR? for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks. The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care.

Endo was established in 1997 through a management buyout from DuPont Merck. The company is based in Chadds Ford, PA and employs more than 1,200 employees throughout the U.S.